Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb AST-3424 vs Regorafenib in AKR1C3-high Advanced Hepatocellular Carcinoma After Immunotherapy
ChiCTR2500114071Phase 2Not yet recruiting
- Sponsor
- Nanjing Tianyinshan Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of odafosfamide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Nanjing Tianyinshan Hospital. Primary endpoints: 9-month overall survival rate and Safety-related observations (adverse events). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
odafosfamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500114071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114071.